Search | Clinical Trials Finder

Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions: DNA analysis, mutation analysis, polymorphism analysis, laboratory biomarker analysis, evaluation of cancer risk factors; Genetic · Other · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
Interventions: RLY-2608, Fulvestrant, Palbociclib 125mg, Ribociclib 400mg, Ribociclib 600mg, PF-07220060 100mg, PF-07220060 300 mg; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 24
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more

Conditions: Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
Interventions: OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib; Drug
Lead sponsor: OnKure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 9 more

Conditions: BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions: Denosumab, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2033
U.S. locations: 47
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 61
States / cities: Daphne, Alabama • Auburn, California • Glendale, California + 54 more

Conditions: Malignant Neoplasm
Interventions: ponatinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Advanced/Metastatic Solid Tumors
Interventions: NMS-03305293; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions: ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more

Conditions: BRAFV600 Mutation, Stage IV Melanoma
Interventions: Radiation therapy, Vemurafenib; Radiation · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
Interventions: RXDX-105; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Sotorasib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
Interventions: Ziftomenib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Columbus, Ohio

Conditions: Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions: Osimertinib, Osimertinib + Chemotherapy; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 146
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 13
States / cities: Stanford, California • Washington D.C., District of Columbia • Weston, Florida + 10 more

Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions: Talazoparib Tosylate; Drug
Lead sponsor: Melinda Telli; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions: FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin; Drug · Biological
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more

Conditions: EGFR T790M Mutation Positive NSCLC
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Anaheim, California • Beverly Hills, California • Burbank, California + 29 more

Conditions: Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Interventions: CEP-701 (Lestaurtinib); Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 7
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more

Conditions: Malignant Melanoma
Interventions: Vemurafenib, Dacarbazine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Cancer
Interventions: GSK2118436, GSK1120212, Other approved anti-cancer agent; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 25
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more

Conditions: Pancreatic Cancer
Interventions: RUCAPARIB; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions: Palbociclib, Olaparib, Fulvestrant; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 192
States / cities: Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more

Conditions: Cancer, Breast Cancer, Colon Cancer, Cervical Cancer, Uterine Cancer, Ovarian Cancer
Interventions: Very low carbohydrate diet (approximately 20 grams per day); Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Radiation Use During Vemurafenib Treatment

Continued Access to RXDX-105

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Ziftomenib Maintenance Post Allo-HCT

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

AZD9291 US Expanded Access Program

CEP-701 (Lestaurtinib) in Myelofibrosis

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer